(CLOV) Clover Health Investments - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US18914F1030
CLOV: Medicare, Plans, Software, Insurance, Healthcare, Services, Platform
Clover Health Investments Corp (NASDAQ: CLOV) stands at the intersection of healthcare and technology, offering Medicare Advantage plans with a twist of innovation. Their approach is rooted in data-driven insights, leveraging a cloud-based platform, Clover Assistant, which empowers physicians to predict and manage chronic diseases earlier and more effectively. This tool aggregates data from diverse sources, enabling doctors to make informed decisions, a hallmark of value-based care. Headquartered in Franklin, Tennessee, Clover Health operates in two segments: Insurance and Non-Insurance, distinguishing itself as a tech-driven insurer in a traditional field.
With a market capitalization of $2.16 billion, Clover Health presents an intriguing case for investors. The P/S ratio of 1.02 reflects revenue generation aligned with market value, while a P/B ratio of 6.33 hints at high growth expectations. As a pioneer in value-based care, Clover Health aligns payment with patient outcomes, aiming to reduce costs and enhance quality. This strategic positioning in a rapidly evolving industry underscores their potential as a disruptor, making them a notable entity for those eyeing the healthcare technology landscape.
Additional Sources for CLOV Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLOV Stock Overview
Market Cap in USD | 1,768m |
Sector | Healthcare |
Industry | Healthcare Plans |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2001-01-02 |
CLOV Stock Ratings
Growth 5y | -39.3% |
Fundamental | -23.6% |
Dividend | 0.0% |
Rel. Strength Industry | 400 |
Analysts | 4/5 |
Fair Price Momentum | 3.31 USD |
Fair Price DCF | 0.50 USD |
CLOV Dividends
No Dividends PaidCLOV Growth Ratios
Growth Correlation 3m | 49.9% |
Growth Correlation 12m | 91.3% |
Growth Correlation 5y | -67.6% |
CAGR 5y | -19.37% |
CAGR/Max DD 5y | -0.20 |
Sharpe Ratio 12m | 0.84 |
Alpha | 384.35 |
Beta | 2.51 |
Volatility | 88.58% |
Current Volume | 5221.6k |
Average Volume 20d | 6549.7k |
As of March 15, 2025, the stock is trading at USD 3.66 with a total of 5,221,611 shares traded.
Over the past week, the price has changed by +0.55%, over one month by -17.94%, over three months by +17.31% and over the past year by +404.83%.
Neither. Based on ValueRay Fundamental Analyses, Clover Health Investments is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -23.57 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLOV as of March 2025 is 3.31. This means that CLOV is currently overvalued and has a potential downside of -9.56%.
Clover Health Investments has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy CLOV.
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CLOV Clover Health Investments will be worth about 3.9 in March 2026. The stock is currently trading at 3.66. This means that the stock has a potential upside of +6.28%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 4.8 | 29.8% |
Analysts Target Price | 4.7 | 27.9% |
ValueRay Target Price | 3.9 | 6.3% |